(12) **Translation of European patent specification**

(11) **NO/EP 2998289 B1**

(19) NO

NORWAY

(51) Int Cl.
C07C 237/08 (2006.01)
A61K 9/127 (2006.01)
A61K 31/16 (2006.01)
A61P 1/16 (2006.01)
C07C 237/22 (2006.01)
C07C 323/60 (2006.01)
C07C 333/04 (2006.01)

Norwegian Industrial Property Office

(21)	Translation Published	2019.10.21
(80)	Date of The European Patent Office Publication of the Granted Patent	2019.08.07
(86)	European Application Nr.	15181729.3
(86)	European Filing Date	2012.06.08
(87)	The European Application's Publication Date	2016.03.23
(30)	Priority	2011.06.08, US, 201161494710 P 2011.06.08, US, 201161494840 P
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
(73)	Proprietor	NITTO DENKO CORPORATION, 1-1-2, Shimohozumi, Ibaraki-shi, Osaka 567-8680, Japan
(72)	Inventor	Sridhar, C. Nagarajan, 3998 Saint Agnes Court, San Diego, CA 92122, USA Karmali, Priya, 4353 Nobel Drive, Unit 68, San Diego, CA 92122, USA Payne, Joseph E., 4810 Milano Way, Oceanside, CA 92057, USA Hou, Zheng, 8305 Stage Coach Place, San Diego, CA 92129, USA Gaudette, John A., 14329 Jolley Lane, Poway, CA 92064, USA Knopov, Victor, 2104 SeaCliff Way, Oceanside, CA 92056, USA Witte, Richard P., 3462 Spring Tide Terrace, San Diego, CA 92110, USA Ahmadian, Mohammad, 3230 Rancho Quartillo, Carlsbad, CA 92009, USA Perelman, Loren A., 855 Cowles Mountain Ct. A22, San Diego, CA 92119, USA Tanaka, Yasunobu, 1-1-2 Shimohozumi Ibaraki, Osaka, 567-8680, Japan Akopian, Violetta, 2308 Seacliff Way, Oceanside, CA 92056, USA Niitsu, Yoshiro, 2-1-901 Kita 3-joNishi 30-chomeChuo-ku, Sapporo-shiHokkaido 064-0823, Japan
(74)	Agent or Attorney	BRYN AARFLOT AS, Stortingsgata 8, 0161 OSLO, Norge

(54) Title **COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING SIRNA ACTIVITY**

(56) References Cited:

WO-A1-03/037385

DATABASE CA [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 1998, DIEC, KHIET HIEN ET AL: "Cosmetic or dermatological crosslinked microemulsions", XP002690326, retrieved from STN Database accession no. 1998:239092 & DE 196 41 672 A1 (BEIERSDORF A.-G., GERMANY; DIEC, KHIET HIEN; MEIER, WOLFGANG; SCHREIBE) 16 April 1998 (1998-04-16)

LI JING ET AL: "Synthesis of polyethylene glycol (PEG) derivatives and PEGylated-peptide biopolymer conjugates", BIOMACROMOLECULES, AMERICAN CHEMICAL SOCIETY; US, vol. 4, no. 4, 17 May 2003 (2003-05-17), pages 1055-1067, XP002328259, ISSN: 1525-7797, DOI: 10.1021/BM034069L

DATABASE CA [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 1998, SCHREIBER, JOERG ET AL: "Crosslinked structures with double lipid membranes or based on peptides", XP002690327, retrieved from STN Database accession no. 1998:208404 -& WO 98/13025 A1 (BEIERSDORF A.-G., GERMANY; SCHREIBER, JOERG; MEIER, WOLFGANG) 2 April 1998 (1998-04-02)

DATABASE CA [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; NIITSU, YOSHIRO ET AL: "Retinoid-liposomes for enhancing modulation of human hsp47 expression for treatment of fibrosis", XP002690328, retrieved from STN Database accession no. 2012:1819002 & WO 2012/170957 A2 (NITTO DENKO CORP [JP]; QUARK PHARMACEUTICALS INC [US]; NNTSU YOSHIRO []) 13 December 2012 (2012-12-13)

MOON ET AL: "Regulation of adipocyte differentiation by PEGylated all-trans retinoic acid: reduced cytotoxicity and attenuated lipid accumulation", JOURNAL OF NUTRITIONAL BIOCHEMISTRY, BUTTERWORTH PUBLISHERS, STONEHAM, GB, vol. 18, no. 5, 19 April 2007 (2007-04-19) , pages 322-331, XP022035106, ISSN: 0955-2863, DOI: 10.1016/J.JNUTBIO.2006.06.004

DATABASE CA [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 2003, BENTLEY, MICHAEL DAVID ET AL: "Water-soluble polymer conjugates of retinoic acid", XP002690324, retrieved from STN Database accession no. 2003:356296 & WO 03/037385 A1 (SHEARWATER CORP [US]; BENTLEY MICHAEL DAVID [US]; ZHAO XUAN [US]; LEAC) 8 May 2003 (2003-05-08)

DATABASE CA [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 1999, SCHREIBER, JORG ET AL: "Disperse multiphase systems linked by covalent bonds into a network", XP002690325, retrieved from STN Database accession no. 1999:12437

DATABASE CA [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 8 April 2011 (2011-04-08), HADA, MAGDOLNA ET AL: "The first synthesis of PEG-carotenoid conjugates", XP002690323, retrieved from STN Database accession no. 2011:648518 & MAGDOLNA HDA ET AL: "The first synthesis of PEGcarotenoid conjugates", TETRAHEDRON LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 52, no. 25, 8 April 2011 (2011-04-08) , pages 3195-3197, XP028212363, ISSN: 0040-4039, DOI: 10.1016/J.TETLET.2011.04.039 [retrieved on 2011-04-15]

Patentkrav

1. Forbindelse for å lette medikamentleveranse til en målcelle, bestående av strukturen $(retinoid)_m$-linker-$(retinoid)_n$; hvor retinoidet er valgt fra gruppen bestående av vitamin A, retinsyre, tretinoin, adapalen, 4-hydroksy(fenyl)retinamid (4-HPR), retinylpalmitat, retinal, mettet retinsyre og mettet, demetylert retinsyre; hvor m og n uavhengig er 2 eller 3; og hvor bindingene er valgt fra gruppen bestående av bis-amido-PEG, tris-amido-PEG, tetra-amido-PEG, Lys-bis-amido-PEG-Lys, Lys-tris-amido-PEG-Lys, Lys-tetra-amido-PEG-Lys, Lys-PEG-Lys, PEG2000, PEG1250, PEG1000, PEG750, PEG550 og PEG-Glu.

2. Forbindelse ifølge krav 1, valgt fra gruppen bestående av $(retinoid)_2$-PEG-$(retinoid)_2$, $(retinoid)_2$-bis-amido-PEG-$(retinoid)_2$ og $(retinoid)_2$-Lys-bis-amido-PEG-Lys-$(retinoid)_2$.

3. Forbindelse ifølge krav 2, hvor forbindelsen har formel



hvor q, r og s er hver uavhengig 1, 2, 3, 4, 5, 6, 7, 8, 9 eller 10.

4. Forbindelsen ifølge hvilket som helst av kravene 1-3, hvor forbindelsen er valgt fra hvilken som helst med strukturene nedenfor:

Lipidnavn	Forbindelse Struktur
DiVA	
DiVA-PEG18	

Lipidnavn	Forbindelse Struktur
TriVA	
DiVA-242	

5. Preparat omfattende forbindelse ifølge krav 1-4.

6. Preparat ifølge krav 5, videre omfattende et liposomalpreparat.

7. Preparat ifølge krav 6, hvor liposomalpreparatet omfatter en lipidblære omfattende et dobbeltlag av lipidmolekyler.

8. Preparat ifølge krav 7, hvor lipidmolekylene omfatte én eller flere lipider valgt fra gruppen bestående av



HEDC,



DODC,



HEDODC,



DSPE,



DOPE,



og DC-6-14.

9. Preparat ifølge krav 8, hvor lipidmolekylene videre omfatter



S104.

10. Preparatet ifølge hvilket som helst av kravene 5-9, videre omfattende en nukleinsyre.

11. Farmasøytisk formulering omfattende forbindelsen ifølge hvilket som helst av kravene 1 til 4 eller preparat ifølge krav 5, en farmasøytisk akseptabel bærer eller fortynningsmiddel og minst ett terapeutisk middel.

12. Farmasøytiske formulering ifølge krav 11, hvor det terapeutiske midlet er en siRNA.

13. Farmasøytiske formulering ifølge krav 12, hvor siRNA har en sekvens valgt fra SEKV ID NR: 1, SEKV ID NR: 2, SEKV ID NR: 3 og SEKV ID NR: 4.